Xatral SR

Xatral SR may be available in the countries listed below.

Ingredient matches for Xatral SR

Alfuzosin

Alfuzosin is reported as an ingredient of Xatral SR in the following countries:

• Australia


• Lithuania

International Drug Name Search

L-Thyroxine SERB

L-Thyroxine SERB may be available in the countries listed below.

Ingredient matches for L-Thyroxine SERB

Levothyroxine

Levothyroxine sodium salt (a derivative of Levothyroxine) is reported as an ingredient of L-Thyroxine SERB in the following countries:

• France

International Drug Name Search

Bezafibrat Arcana

Bezafibrat Arcana may be available in the countries listed below.

Ingredient matches for Bezafibrat Arcana

Bezafibrate

Bezafibrate is reported as an ingredient of Bezafibrat Arcana in the following countries:

• Austria

International Drug Name Search

Levofloxacina Farmoz

Levofloxacina Farmoz may be available in the countries listed below.

Ingredient matches for Levofloxacina Farmoz

Levofloxacin

Levofloxacin is reported as an ingredient of Levofloxacina Farmoz in the following countries:

• Portugal

International Drug Name Search

Kerato Biciron

Kerato Biciron may be available in the countries listed below.

Ingredient matches for Kerato Biciron

Calcium Pantothenate

Calcium Pantothenate is reported as an ingredient of Kerato Biciron in the following countries:

• Germany

International Drug Name Search

Nexplanon

Nexplanon is a brand name of etonogestrel, approved by the FDA in the following formulation(s):

NEXPLANON (etonogestrel - implant; implantation)

• 
  Manufacturer: ORGANON USA INC
  
  Approval date: May 31, 2011
  
  Strength(s): 68MG/IMPLANT ^[RLD]

Has a generic version of Nexplanon been approved?

No. There is currently no therapeutically equivalent version of Nexplanon available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Nexplanon. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Nexplanon.

See also...

• Nexplanon Advanced Consumer Information (Micromedex)
• Etonogestrel implant Consumer Information (Cerner Multum)
• Etonogestrel Intradermal Advanced Consumer Information (Micromedex)

Kebirzol

Kebirzol may be available in the countries listed below.

Ingredient matches for Kebirzol

Letrozole

Letrozole is reported as an ingredient of Kebirzol in the following countries:

• Argentina

International Drug Name Search

Apo-Diltiaz

Apo-Diltiaz may be available in the countries listed below.

Ingredient matches for Apo-Diltiaz

Diltiazem

Diltiazem hydrochloride (a derivative of Diltiazem) is reported as an ingredient of Apo-Diltiaz in the following countries:

• Canada


• Vietnam

International Drug Name Search

Bovatec 150 FP

Dosage Form: FOR ANIMAL USE ONLY
Bovatec®

150 FP

Brand of lasalocid

Type A Medicated Article

Active ingredient

Each pound contains 150 grams (33.1%) of lasalocid (as lasalocid sodium activity) in a carrier suitable for incorporation in feed.

Important

Handling Information - Must be thoroughly mixed in feeds before use. When mixing and handling lasalocid premix, use protective clothing, impervious gloves and a dust mask. Avoid contact with eyes. Operators should wash hands thoroughly with soap and water after handling.

Mixing directions

This product should be further diluted in an intermediate blending step prior to mixing in the final feed. Do not feed undiluted.

1.

Complete Feed

a.

Intermediate blending: Mix 1 part of Bovatec 150 FP (Type A Medicated Article) with 29 parts of finely ground nonmedicated feedstuffs to provide an intermediate premix containing 5 grams of lasalocid per pound.

b.

Using the 5 g/lb intermediate premix, the following table would apply to the manufacture of complete feeds:

Intended lasalocid concentration in the complete feed		Add the following amounts of 5 grams per pound intermediate premix per ton of complete feed mixed:
grams/ton	mg/lb	lbs/ton
* Maximum approved concentration for complete feeds for feedlot cattle and sheep in confinement
10	5	2
15	7.5	3
30*	15	6

 

 

c.

Using the 5 g/lb intermediate premix, the following table would apply to the manufacture of other complete feeds and supplements that do not require further mixing:

Daily feeding rate	Desired daily lasalocid intake	Add the following amounts of 5 grams per pound intermediate premix per ton of feed or supplement mixed:	Lasalocid will be present in the feed or supplement at the following concentration:
lbs/head/day	mg/head/day	lbs/ton	grams/ton
1	60	24	120
	200	80	400
	300	120	600
2	60	12	60
	200	40	200
	300	60	300
3	60	8	40
	200	26.7	133.5
	300	40	200

2.

Dry Supplement

a.

Intermediate blending: Mix 1 part Bovatec 150 FP premix (Type A Medicated Article) with 6.5 parts of finely ground nonmedicated feedstuffs to provide an intermediate premix containing 20 grams of lasalocid per pound. For example, mix one 50 lb bag of Bovatec 150 FP premix with 325 lbs of non-medicated feedstuffs.

b.

Using the 20 g/lb intermediate premix, the following table would apply to the manufacture of dry supplements:

Intended lasalocid concentration in the supplement		Add the following amounts of 20 grams per pound intermediate premix per ton of supplement mixed:
grams/ton	mg/lb	lbs/ton
400	200	20
600	300	30
1000	500	50
1440	720	72
1600	800	80

 

 

c.

Thoroughly mix supplement with sufficient non-medicated feedstuffs in accordance with the feeding rates listed in the use directions below.

3.

Liquid Supplement Intended for Addition to Dry Feeds

a.

Supplements with suspending agent(s) should be in a pH range of 4-8 and maintain physical stability for up to three months with a viscosity not less than 300 cps.

b.

Conventional liquid supplements should be in a pH range of 4-8.

 

For liquid feeds stored in recirculating tank systems: Recirculate immediately prior to use for no less than 10 minutes, moving not less than 1 percent of the tank contents per minute from the bottom of the tank to the top. Recirculate daily as described even when not used.

 

For liquid feeds stored in mechanical, air, or other agitation-type tank systems: Agitate immediately prior to use for not less than 10 minutes, creating a turbulence at the bottom of the tank that is visible at the top. Agitate daily as described even when not used.

Use directions

Species	Dose	Indications for use
Feedlot Cattle	10-30 grams lasalocid per ton of total ration (90% dry matter)	For improved feed efficiency in cattle being fed in confinement for slaughter, feed continuously to provide not less than 100 mg nor more than 360 mg per head per day.
	25-30 grams lasalocid per ton of total ration (90% dry matter)	For improved feed efficiency and increased rate of weight gain in cattle being fed in confinement for slaughter, feed continuously to provide not less than 250 mg nor more than 360 mg per head per day.
Pasture Cattle – slaughter, stocker, feeder cattle, and dairy and beef replacement heifers	60-300 mg lasalocid per head/day	For increased rate of weight gain. The drug must be contained in at least 1 pound of feed and fed continuously on a daily basis.
	60-300 mg lasalocid per head/day	For increased rate of weight gain, feed continuously on a free-choice basis. (Manufacture of Type C free-choice feeds from this product requires a Medicated Feed License Application approved by FDA.)
		Daily lasalocid intakes in excess of 200 mg per head per day have not been shown to be more effective than 200 mg lasalocid per head per day.
		NOTE: Coccidiosis may occur when young pasture cattle are co-mingled with adult cattle passing coccidial oocysts.
Cattle	1 mg lasalocid per 2.2 lbs body weight/day	For control of coccidiosis caused by Eimeria bovis and E. zuernii in cattle up to 800 lbs. Hand feed continuously to provide not more than 360 mg per day.
Sheep	20-30 grams lasalocid per ton of total ration (90% dry matter)	For prevention of coccidiosis caused by Eimeria ovina, E. crandallis, E. ovinoidalis (E. ninakohlyakimovae), E. parva, and E. intricata in sheep maintained in confinement. Feed continuously to provide not less than 15 mg nor more than 70 mg per head per day depending on body weight.

Caution

Animal Safety - Do not allow horses or other equines access to premixes or supplements containing lasalocid, as ingestion may be fatal. The safety of lasalocid in unapproved species has not been established. Feeding undiluted or mixing errors resulting in excessive concentrations of lasalocid could be fatal to cattle and sheep.

Warning

A withdrawal period has not been established for this product in pre-ruminating calves.

Do not use in calves to be processed for veal.

NADA 96-298, Approved by FDA. Not for human use.

Marketed by

Alpharma Inc.

Bridgewater, New Jersey 08807

Net wt 50 LB (22.68 kg)

Trademarks registered

by Alpharma Inc.

Made in USA

710316 0910

PRINCIPAL DISPLAY PANEL - 50 lb Bag

Bovatec®

150 FP

ALPHARMA

Brand of lasalocid

Type A Medicated Article

See back panel for use directions

Net wt 50 LB (22.68 kg)

ALPHARMA®

Bovatec®

150 FP

BOVATEC 150FP  lasalocid sodium  powder

Product Information Product Type OTC TYPE A MEDICATED ARTICLE ANIMAL DRUG NDC Product Code (Source) 46573-457 Route of Administration ORAL DEA Schedule

Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength Lasalocid Sodium (Lasalocid) Lasalocid Sodium 150 g  in 0.45 kg

Inactive Ingredients Ingredient Name Strength No Inactive Ingredients Found

Product Characteristics Color WHITE (white to tan) Score      Shape Size Flavor Imprint Code Contains

Packaging # NDC Package Description Multilevel Packaging 1 46573-457-00 22.68 kg In 1 BAG None

Marketing Information
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NADA	NADA096298	01/01/2009

Labeler - Alpharma Inc. Animal Health (070954094)

Revised: 11/2009Alpharma Inc. Animal Health

Shacillin

Shacillin may be available in the countries listed below.

Ingredient matches for Shacillin

Ampicillin

Ampicillin is reported as an ingredient of Shacillin in the following countries:

• Iraq


• Yemen

International Drug Name Search

Conray

Conray is a brand name of iothalamate, approved by the FDA in the following formulation(s):

CONRAY (iothalamate meglumine - injectable; injection)

• 
  Manufacturer: MALLINCKRODT
  
  Approved Prior to Jan 1, 1982
  
  Strength(s): 60% ^[RLD]

Has a generic version of Conray been approved?

No. There is currently no therapeutically equivalent version of Conray available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Conray. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Conray.

See also...